Which genetic lung cancer does Osimertinib treat?

Osimertinib, also known as osimertinib, is a highly effective lung cancer targeted drug mainly used to treat patients with non-small cell lung cancer who carry specificEGFR (epidermal growth factor receptor) gene mutations.

Osimertinib is a highly selective EGFR mutant inhibitor that inhibits the growth and spread of tumor cells by blocking the EGFR signaling pathway. EGFR is one of the most common types of gene mutations in lung cancer, especially in lung adenocarcinoma, where the EGFR gene mutation rate is the highest.

1.ForEGFR T790M mutation: Osimertinib is particularly suitable for patients with advanced non-small cell lung cancer who have developed resistance after receiving first- or second-generation EGFR inhibitors (such as gefitinib, erlotinib, icotinib or afatinib) and whose genetic testing has revealed the T790M mutation. T790M mutation is one of the main mechanisms of resistance to EGFR inhibitors, and osimertinib can exert a strong inhibitory effect on this mutation.

2.For other EGFR mutation types: Although osimertinib primarily targets the T790M mutation, it may also be effective against other EGF Rmutation types (such as 19 exon deletion and 21exon L858R point mutation) have a certain inhibitory effect. However, for these mutation types, the efficacy of osimertinib may not be as dramatic as for the T790M mutation.

Multiple studies have shown that osimertinib has a significant therapeutic effect on patients with non-small cell lung cancer carrying EGFR mutations. For example, the LAURA study showed that osimertinib can significantly improve the operability and survival of tumors.EGFRProgression-free survival in patients with non-metastatic non-small cell lung cancer harboring gene mutations. Specifically, patients who received standard therapy alone had a median progression-free survival of 5.6 months, while patients who also received osimertinib had a median progression-free survival of 39.1 months.

Osimertinib is mainly used to treat patients with non-small cell lung cancer carrying EGFR T790M mutation and other EGFR mutation types. By blocking the EGFR signaling pathway, osimertinib can inhibit the growth and spread of tumor cells and provide patients with effective treatment options.